The latest announcement is out from Aptose Biosciences ( (TSE:APS) ).
On March 17, 2025, Aptose Biosciences announced it regained compliance with Nasdaq’s minimum bid price requirement, as its shares maintained a closing bid price of $1.00 or greater for ten consecutive business days. However, Aptose is still not in compliance with the $2.5 million requirement and is operating under an exception granted by the Hearing Panel, which provides additional time to regain full compliance.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. The company is advancing a pipeline of small molecule cancer therapeutics, including its lead compound tuspetinib (TUS), an oral kinase inhibitor for treating acute myeloid leukemia (AML).
YTD Price Performance: -45.41%
Average Trading Volume: 439,572
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $8.14M
Learn more about APS stock on TipRanks’ Stock Analysis page.